Abstract
The WORC database consists in total of 930 patients composed of six datasets gathered at the Erasmus MC, consisting of patients with: 1) well-differentiated liposarcoma or lipoma (115 patients); 2) desmoid-type fibromatosis or extremity soft-tissue sarcomas (203 patients); 3) primary solid liver tumors, either malignant (hepatocellular carcinoma or intrahepatic cholangiocarcinoma) or benign (hepatocellular adenoma or focal nodular hyperplasia) (186 patients); 4) gastrointestinal stromal tumors (GISTs) and intra-abdominal gastrointestinal tumors radiologically resembling GISTs (246 patients); 5) colorectal liver metastases (77 patients); and 6) lung metastases of metastatic melanoma (103 patients). For each patient, either a magnetic resonance imaging (MRI) or computed tomography (CT) scan, collected from routine clinical care, one or multiple (semi-)automatic lesion segmentations, and ground truth labels from a gold standard (e.g., pathologically proven) are available. All datasets are multicenter imaging datasets, as patients referred to our institute often received imaging at their referring hospital. The dataset can be used to validate or develop radiomics methods, i.e., using machine or deep learning to relate the visual appearance to the ground truth labels, and automatic segmentation methods. See also the research article related to this dataset: Starmans et al., Reproducible radiomics through automated machine learning validated on twelve clinical applications, Submitted.
Competing Interest Statement
Wiro J. Niessen is founder, scientific lead, and shareholder of Quantib BV. Jacob J. Visser is a medical advisor at Contextflow. Astrid A. M. van der Veldt is a consultant (fees paid to the institute) at BMS, Merck, MSD, Sanofi, Eisai, Pfizer, Roche, Novartis, Pierre Fabre and Ipsen. The other authors do not declare any conflicts of interest.
Funding Statement
This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study protocol for the collection of the WORC database conformed to the ethical guidelines of the 1975 Declaration of Helsinki. Approval by the local institutional review board of the Erasmus MC (Rotterdam, the Netherlands) was obtained for collection of the WORC database (MEC-2020-0961), and separately for the six included studies (Lipo: MEC-2016-339, Desmoid: MEC-2016-339, Liver: MEC-2017-1035, GIST: MEC-2017-1187, CRLM: MEC-2017-479, Melanoma: MEC-2019-0693). The need for informed consent was waived due to the use of anonymized, retrospective data.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
⋆ Workflow for Optimal Radiomics Classification
Data Availability
The data referred to in this manuscript is publicly available at https://xnat.bmia.nl/data/projects/worc. The code to download the data and reproduce the experiments from the radiomics study in which this data was presented can be found at https://github.com/MStarmans91/WORCDatabase.